289 related articles for article (PubMed ID: 9763553)
1. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.
Federici AB; Stabile F; Castaman G; Canciani MT; Mannucci PM
Blood; 1998 Oct; 92(8):2707-11. PubMed ID: 9763553
[TBL] [Abstract][Full Text] [Related]
2. Acquired von Willebrand syndrome associated with monoclonal gammopathy: a single-center study of 36 patients.
Voisin S; Hamidou M; Lefrançois A; Sigaud M; Mahé B; Trossaërt M
Medicine (Baltimore); 2011 Nov; 90(6):404-411. PubMed ID: 22033454
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of inhibitors in acquired von Willebrand syndrome.
Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
[TBL] [Abstract][Full Text] [Related]
4. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate.
Castaman G; Tosetto A; Rodeghiero F
Am J Hematol; 1992 Oct; 41(2):132-6. PubMed ID: 1415174
[TBL] [Abstract][Full Text] [Related]
6. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
Federici AB
Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
[TBL] [Abstract][Full Text] [Related]
7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
8. Acquired von Willebrand syndrome: features and management.
Mohri H
Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease.
van Genderen PJ; Michiels JJ; Bakker JJ; van 't Veer MB
Vox Sang; 1994; 67(1):14-7. PubMed ID: 7975445
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Lavin M; Brophy TM; Rawley O; O'Sullivan JM; Hayden PJ; Browne PV; Ryan K; O'Connell N; O'Donnell JS
J Thromb Haemost; 2016 Jun; 14(6):1200-5. PubMed ID: 26991062
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and management of von Willebrand disease].
Higasa S; Tokugawa T; Sawada A
Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
[TBL] [Abstract][Full Text] [Related]
12. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
13. [Acquired von Willebrand syndrome].
de Lange DW; Fijnheer R; Wittebol S
Ned Tijdschr Geneeskd; 2003 Sep; 147(37):1808-11. PubMed ID: 14526622
[TBL] [Abstract][Full Text] [Related]
14. Acquired von Willebrand syndrome: an update.
Franchini M; Lippi G
Am J Hematol; 2007 May; 82(5):368-75. PubMed ID: 17133419
[TBL] [Abstract][Full Text] [Related]
15. Treatment of von Willebrand disease.
Rodeghiero F; Castaman G
Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
[TBL] [Abstract][Full Text] [Related]
16. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
Federici AB; Mannucci PM
Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
[TBL] [Abstract][Full Text] [Related]
17. Advances in the therapy of von Willebrand disease.
Batlle J; Noya MS; Giangrande P; Lopez-Fernandez MF
Haemophilia; 2002 May; 8(3):301-7. PubMed ID: 12010427
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic approaches to acquired von Willebrand syndrome.
Federici AB
Expert Opin Investig Drugs; 2000 Feb; 9(2):347-54. PubMed ID: 11060681
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
